Navigation Links
Osteotech Receives FDA Clearance for its Next Generation Grafting Material
Date:10/29/2008

EATONTOWN, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative healing, announced today that it has received 510(k) clearance from the United States Food and Drug Administration ("FDA") for its next generation grafting material. Osteotech received 510(k) clearance for this material as a bone graft substitute, and as a bone void filler, for use in the spine, pelvis and extremities.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "Receiving FDA clearance for our next generation grafting material is a great accomplishment for our team and another key milestone in our strategic plan. During our November 7, 2008 conference call, we will provide much more insight into this grafting material, its procedural uses and the timeline for introduction."

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, or this press release, please go to Osteotech's website at http://www.osteotech.com.

This press release may contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward- looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could affect these results are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
2. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
3. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
4. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
5. Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
6. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
7. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
8. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
9. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
10. Osteotech to Present at the Sidoti Conference in New York
11. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):